2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. 5 alpha Reductase

5 alpha Reductase

5α-reductase

5 alpha Reductase

Related Products

PDF 0.22 MB

Steroid 5-α reductase (5AR) is a membrane-bound protein that is responsible for reducing steroids such as testosterone, progesterone, and androstenedione to 5-α reduced metabolites such as 5-α dihydrotestosterone (DHT), 5-α dihydroprogesterone and androstanedione, respectively. There are three isoforms of 5AR in humans: SRD5A1, SRD5A2, and SRD5A3. SRD5A1 and SRD5A2 have functionality for 5-α reduction of steroids in humans. DHT is a more potent androgen than testosterone and has a function in androgen receptor activation.

The inactivating mutations in 5αR2 lead to disorders of sexual development. The regulation of 5AR is important for the treatment of benign prostate hyperplasia (BPH) and prostate cancer (PC), and 5AR inhibitors are widely used for the treatment of androgen-dependent benign or malignant prostatic diseases.

5 alpha Reductase Related Products (37):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-133949
    8,11-Eicosadiynoic acid
    		Inhibitor
    8,11-Eicosadiynoic acid, an unsaturated fatty acid, is a steroid 5α-reductase inhibitor. 8,11-Eicosadiynoic acid can be used for the research of acne.
    8,11-Eicosadiynoic acid
  • HY-118091A
    Bexlosteride
    		Inhibitor
    Bexlosteride (LY300502) is a benzoquinolinone human type I 5α-reductase inhibitor. Bexlosteride shows metabolic inhibitory, antiproliferative, and antisecretory effects in LNCaP human prostatic adenocarcinoma cell cultures. Bexlosteride can be used for the research of prostatic cancer.
    Bexlosteride
  • HY-13613S
    Dutasteride-13C6
    Dutasteride-13C6 is the 13C labeled Dutasteride[1]. Dutasteride (GG745) is a potent inhibitor of both 5α-reductase isozymes. Dutasteride may possess off-target effects on the androgen receptor (AR) due to its structural similarity to DHT[2].
    Dutasteride-<sup>13</sup>C<sub>6</sub>
  • HY-125065
    MK-4541
    		Antagonist
    MK-4541 is an orally active and selective androgen receptor (AR) modulator. MK-4541 acts as an antagonist to inhibit 5α-reductase. MK-4541 inhibits proliferation and induces apoptosis in AR positive prostate cancer cells. MK-4541 significantly inhibited the growth of R3327-G prostate tumors in xenograft mouse model.
    MK-4541
  • HY-13635S
    Finasteride-d9
    		Inhibitor 99.13%
    Finasteride-d9 is deuterium labeled Finasteride. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia[1][2][3].
    Finasteride-d<sub>9</sub>
  • HY-13613S2
    Dutasteride-13C,15N,d
    		Inhibitor
    Dutasteride-13C,15N,d is 15N and deuterated labeled Dutasteride (HY-13613). Dutasteride (GG745) is a potent inhibitor of both 5α-reductase isozymes. Dutasteride may possess off-target effects on the androgen receptor (AR) due to its structural similarity to DHT.
    Dutasteride-<sup>13</sup>C,<sup>15</sup>N,d
  • HY-13635R
    Finasteride (Standard)
    		Inhibitor
    Finasteride (Standard) is the analytical standard of Finasteride. This product is intended for research and analytical applications. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia.
    Finasteride (Standard)
  • HY-118091
    LY191704
    		Inhibitor
    LY191704, as a benzoquinolinone, is a potent, nonsteroidal, noncompetitive and selective human type I 5α-reductase inhibitor. LY191704 is a racemic mixture of the compounds LY300502 and LY300503. LY191704 may be useful in the research of human endocrine disorders associated with overproduction of dihydrotestosterone (DHT) by 5α-reductase type 1.
    LY191704
  • HY-121700
    L-751788
    		Inhibitor
    L-751788 is a selective inhibitor of type I of 5α-reductase. L-751788 does not have a significant impact on the differentiation of the external genitalia in animals. When administered orally to pregnant rhesus monkeys, L-751788 (2, 10 mg/kg) did not cause abnormalities in fetal external genitalia.
    L-751788
  • HY-165595
    Glutamic acid-alanine-glycine mixture
    		Activator
    The glutamic acid-alanine-glycine mixture is an orally active activator of testosterone 5α-reductase (5α-reductase). It promotes prostate function by enhancing the activity of 5α-reductase and increasing the levels of free amino acids. However, when combined with testosterone and estradiol (HY-B0141R), the glutamic acid-alanine-glycine mixture inhibits 5α-reductase activity and decreases the levels of free amino acids. The glutamic acid-alanine-glycine mixture can be used in research related to prostate function and endocrine disorders.
    Glutamic acid-alanine-glycine mixture
  • HY-13635A
    Finasteride acetate
    		Inhibitor
    Finasteride (MK-906) acetate is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride acetate has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride acetate can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia.
    Finasteride acetate
  • HY-N13195
    (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one
    		Inhibitor
    (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one shows a 5a-reductase inhibitory activity with an IC50 value of 41.9 μM. (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one inhibits the growth of the ventral prostate induced by testosterone in rat. (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one is promising for research of benign prostatic hyperplasia (BPH) as well as other 5α-dihydrotestosterone (DHT)-related disorders, such as acne and male pattern baldness.
    (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one
  • HY-105217
    Turosteride
    		Inhibitor
    Turosteride is a selective 5 alpha-reductase inhibitor, with IC50 values of 55 and 53 nM for human and rat prostatic 5 alpha-reductases, respectively. Turosteride can reduce the prostate and seminal vesicle weights.
    Turosteride
  • HY-123323
    MK-0434
    		Inhibitor
    MK-0434 is an orally active steroid 5α-reductase inhibitor. MK-0434 specifically inhibits steroid 5α-reductase, thereby reducing the level of dihydrotestosterone (DHT) in the body. MK-0434 can be used in the study of benign prostatic hyperplasia.
    MK-0434
  • HY-107385R
    Epristeride (Standard)
    		Inhibitor
    Epristeride (Standard) is the analytical standard of Epristeride. This product is intended for research and analytical applications. Epristeride (ONO-9302) is a selective, specific and orally active uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2. Epristeride has inhibitory effects for SR isoenzymes types 2 with Ki value of 0.7-2 nM. Epristeride can be used for the research of prostatic hyperplasia and acne.
    Epristeride (Standard)
  • HY-19284
    FR-146687
    		Inhibitor
    FR-146687 (FK 687) is a selective and orally active 5α-reductase inhibitor with IC50s of 1.7 nM and 4.6 nM for rat and human 5α-reductases, respectively. FR-146687 shows no inhibitory effects on other steroid oxidoreductases.
    FR-146687
  • HY-U00376
    5α-reductase-IN-1
    		Inhibitor
    5α-reductase-IN-1 is an inhibitor of 5α-reductase, used for the research of patterned alopecia in combination with minoxidil.
    5α-reductase-IN-1